The researchers’ design choice was deliberate. Rather than using electroporation, a common laboratory method that pushes nucleic acids through cell membranes with electric pulses, they encapsulated synthetic anti-CD19 CAR mRNA in LNPs. Their head-to-head comparison was striking: electroporation delivered mRNA into roughly 78 percent of T cells but slashed viability from 97 percent to 49 percent, whereas LNP transfection preserved nearly all cell viability while producing even stronger protein expression relative to the mRNA dose used. The CAR construct itself was a second-generation design based on the FMC63 antibody fragment, coupled to CD8 hinge and transmembrane domains and the 4-1BB and CD3-zeta signaling modules, with a T2A self-cleaving peptide allowing co-expression of an enhanced green fluorescent protein (EGFP) reporter so that translation could be tracked inside each cell.

One of the study’s most intriguing mechanistic findings concerns why activated T cells take up these nanoparticles so efficiently. When the researchers activated freshly isolated human T cells with anti-CD3 and anti-CD28 antibodies plus interleukin-2, they observed upregulation not only of the activation marker CD25 but also of the low-density lipoprotein receptor (LDLR), the same receptor that LNPs exploit when they enter liver cells. Flow cytometry revealed that the T cell population split into two distinct groups after transfection: larger, highly activated cells expressed far more EGFP and CD25 than their smaller, less activated counterparts. This correlation between cell size, activation state, and transfection efficiency suggests that the very process of preparing T cells for CAR engineering also primes their molecular machinery for LNP uptake, a detail that could inform how future non-viral manufacturing protocols are designed.

Macrophages proved to be even more avid recipients of the mRNA than T cells. Quantitative PCR showed that human primary macrophages internalized about 13,693 parts per million of CAR mRNA relative to total RNA, dwarfing the uptake by other cell types tested, including HeLa, fibroblast, and murine cell lines. Flow cytometry confirmed that over 56 percent of transfected macrophages displayed the CAR protein on their surface, and confocal microscopy verified active translation of the EGFP reporter. The expression persisted for 24 to 96 hours after transfection, with the most robust signal lasting up to 48 hours. Because mRNA never enters the nucleus, this transient expression window is a safety feature as much as a limitation: the engineered receptors fade away rather than persisting indefinitely, which could reduce risks such as uncontrolled cell expansion or off-tumor toxicity.

When the team pitted the two engineered cell types against CD19-positive NALM6 leukemia cells, the differences in their effector mechanisms became clear. CAR-T cells were dramatically potent, killing 86 percent of cancer cells at a 10:1 effector-to-target ratio and still eliminating 82 percent at a mere 1:1 ratio, with detectable effects even at 1:20. CAR-macrophages, by contrast, worked through phagocytosis rather than direct cytotoxicity. Viability staining of cancer cells remaining in the supernatant showed that macrophages were not primarily killing their targets from a distance; they were swallowing them whole. Live-cell imaging captured this process in remarkable detail: after roughly 15 hours of co-culture, CAR-macrophages began actively engulfing leukemia cells, and by 24 hours some individual macrophages had consumed multiple cancer cells simultaneously, while control macrophages ignored cancer cells even in direct contact.

The mRNA transfection itself reshaped macrophage behavior in ways that complicate the picture. Gene expression analysis showed that CAR mRNA-LNP treatment upregulated the pro-inflammatory M1 marker TNF while suppressing the M2 marker CCL22, but also increased TGFB, an anti-inflammatory mediator, indicating a mixed polarization state rather than a clean M1 shift. More surprisingly, CAR transfection sharply reduced macrophage motility, from 12.55 nanometers per second in controls to 5.58 nanometers per second after CAR mRNA treatment, and the cells adopted a less elongated, more activated morphology. Since macrophage migration is essential for infiltrating and remodeling tumors, the authors suggest that co-encapsulating motility-restoring RNAs with CAR mRNA in the same nanoparticle could be a rational next step.

Another layer of the study targeted the so-called myeloid checkpoint, the CD47-SIRPA axis that cancer cells exploit to broadcast a don’t-eat-me signal. The researchers found that CAR mRNA transfection, and even control EGFP mRNA, paradoxically upregulated SIRPA, the receptor on macrophages that recognizes CD47 and suppresses phagocytosis. To counteract this, they delivered SIRPA-targeting siRNA either separately or co-encapsulated with CAR mRNA in a single LNP formulation. The combination effectively neutralized the SIRPA upregulation and potentiated phagocytosis beyond what either component achieved alone. Blocking CD47 on the cancer cells with antibodies also modestly increased uptake, and the team showed that apoptotic cancer cells, which express lower levels of CD47, were readily consumed, confirming that manipulating this checkpoint is a viable strategy for boosting macrophage-mediated cancer clearance.

The centerpiece experiment brought everything together in a triple co-culture of CAR-T cells, CAR-macrophages, and fluorescently labeled NALM6 leukemia cells. Live-cell imaging over 24 hours revealed a striking behavioral shift: in control cultures the three cell types remained largely segregated, but after CAR transfection the culture became a web of cell-cell contacts, with macrophages dragging cancer cells and T cells clustering around both. Quantitatively, only 13.87 percent of cancer cells survived in the dual-CAR cultures after 24 hours, compared with 60.26 percent in controls. Crucially, when the team tested 36 different combinations of CAR-T and CAR-macrophage numbers across three donors and analyzed the results with the Loewe additivity model in SynergyFinder, the average synergy score was 10.013, exceeding the accepted threshold of 10, with a peak score of 21.05. This was true synergy, not simple additivity, likely driven by reciprocal cytokine signaling: activated T cells secrete interferon-gamma, which pushes macrophages toward an M1 state, while activated macrophages release TNF, which promotes tumor cell apoptosis and supports T cell function.

The implications extend beyond the laboratory bench. The only CAR-macrophage therapy to reach clinical testing, CT-0508, an anti-HER2 candidate developed with an adenoviral vector and tested in combination with pembrolizumab, has already shown tumor accumulation and expansion of CD8-positive T cells in early trials, lending real-world plausibility to the synergy the Aachen team observed in vitro. An mRNA-LNP approach could make such therapies faster, cheaper, and free of the risks associated with viral genome integration, and the transient expression profile might allow staggered dosing or combination regimens that are difficult with permanently engineered cells. The authors are careful to note the limitations of their work: co-cultures lack the full complexity of the tumor microenvironment, systemic circulation, complement proteins, and the diverse immune populations that shape responses in patients. Still, their central message is compelling and quantitatively grounded. T cells and macrophages engineered with the same CAR mRNA kill leukemia cells through fundamentally different mechanisms, direct cytotoxicity versus phagocytosis, and when deployed together they achieve something neither can accomplish alone. If future in vivo studies confirm that this synergy permits lower cell doses and a wider therapeutic window, the humble lipid nanoparticle, already famous for its role in vaccines, may become the manufacturing backbone of a new generation of dual-cell cancer immunotherapies.

Subject of Research: CAR mRNA lipid nanoparticle engineering of human T cells and macrophages for synergistic clearance of CD19-positive leukemia cells

Article Title: Distinct effector functions and synergy of CAR mRNA-engineered T cells and macrophages in the clearance of CD19 + leukemia cells

Article References: Liao, L., Lin, C., Kuzmanović, A., Wang, N., Jans, A., Penners, C., Ohl, K., Johnen, S., Geczy, R., Rabel, M., Clarke, S., Balgi, A., Liedtke, C., & Bartneck, M. (2026). Distinct effector functions and synergy of CAR mRNA-engineered T cells and macrophages in the clearance of CD19+ leukemia cells. Journal of Advanced Research, 88, 1119-1136. https://doi.org/10.1016/j.jare.2026.01.049

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.049

Keywords: CAR-T cells, CAR-macrophages, lipid nanoparticles, mRNA therapy, CD19, leukemia, phagocytosis, SIRPA, CD47, immunotherapy, synergy, non-viral gene delivery

Efferocytosis unfolds in coordinated stages. Dying cells first release find-me signals, soluble messengers such as nucleotides and lipids that lure phagocytes toward the site of death. Once in contact, the phagocyte probes the surface of the apoptotic cell for eat-me signals, most prominently phosphatidylserine, a phospholipid that flips from the inner leaflet to the outer leaflet of the membrane as a cell dies. Receptors on the macrophage surface engage these markers and trigger cytoskeletal remodeling, engulfment and degradation of the corpse inside a phagolysosome. Crucially, efferocytosis is immunologically silent or even anti-inflammatory: it drives the production of anti-inflammatory mediators such as interleukin-10 and transforming growth factor-beta, and it promotes the resolution phase that follows any inflammatory insult. When the process falters, apoptotic cells progress to secondary necrosis, spilling their contents and sustaining a chronic inflammatory fire that damages surrounding tissue.

CD47 sits at the heart of the regulatory machinery that decides whether engulfment proceeds. This widely expressed cell-surface glycoprotein binds to signal regulatory protein alpha, SIRPα, on macrophages and delivers what immunologists call the classic don’t eat me signal. When CD47 engages SIRPα, the receptor’s cytoplasmic tail recruits tyrosine phosphatases SHP-1 and SHP-2, which dephosphorylate the signaling intermediates needed for phagocytic cup formation. In effect, the macrophage’s engulfment machinery is switched off before it can engage. The system evolved as a self-preservation mechanism: healthy cells display abundant CD47 and are spared from accidental destruction. The landmark work of Oldenborg and colleagues showed that CD47 acts as a marker of self on red blood cells, and that erythrocytes lacking the protein are rapidly cleared from circulation. In this sense, CD47 functions as a passport presented at the macrophage checkpoint.

The trouble begins when pathological cells hijack the passport. Under disease conditions, abnormally high CD47 expression allows abnormal cells to evade immune clearance, and the CD47/SIRPα axis has consequently emerged as a major immune checkpoint in the regulation of efferocytosis. In tumors, the evidence is striking. Majeti and colleagues demonstrated in 2009 that CD47 is upregulated on acute myeloid leukemia stem cells and serves as an adverse prognostic factor, allowing malignant cells to slip past macrophage surveillance. Subsequent studies have traced the mechanisms of this overexpression in remarkable detail. The oncogene MYC directly regulates CD47 transcription alongside PD-L1, coupling proliferative drive with immune evasion. In breast cancer, a CD47-associated super-enhancer links pro-inflammatory signaling to CD47 upregulation, while NF-kappaB signaling drives CD47 overexpression in radioresistant HER2-positive cells. In glioblastoma, EGFR-induced phosphorylation of CD47 blocks its ubiquitination and degradation, stabilizing the protein on the tumor cell surface.

Therapeutically, the don’t eat me signal has become one of the most actively pursued targets in cancer immunology. Anti-CD47 antibodies such as magrolimab and evorpacept block the CD47-SIRPα interaction, releasing the brakes on macrophage phagocytosis and enabling tumor cell engulfment. Clinical studies in hematologic malignancies have combined CD47 blockade with azacitidine and venetoclax in acute myeloid leukemia, and with rituximab and lenalidomide in non-Hodgkin lymphoma, with phase 1 trials reporting encouraging activity. In solid tumors, the strategy is more nuanced. Glioblastoma research showed that microglia, the resident macrophages of the brain, act as effector cells when the CD47-SIRPα axis is disrupted, and that irradiation or temozolomide chemotherapy can sensitize tumors to anti-CD47 treatment. Recent work has explored dual checkpoint blockade, oncolytic viruses that downregulate CD47, HDAC inhibitors that enhance phagocytosis, and histone demethylase inhibitors that suppress CD47 expression in breast cancer, all aimed at amplifying the macrophage attack on malignant cells.

Yet the same pathway that protects tumors also drives cardiovascular disease, and here the therapeutic logic inverts. In atherosclerosis, efferocytosis is essential for clearing apoptotic foam cells within arterial plaques. When macrophages fail to engulf these dying cells, the corpses undergo secondary necrosis and form the necrotic cores that destabilize plaques and precipitate heart attacks. CD47 is upregulated in advanced lesions, partly through noncoding RNA circuits such as the lncRNA MIAT sponge that sequesters miR-149-5p and lifts CD47 expression. Kojima and colleagues reported in Nature that CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis progression in mice, and subsequent studies showed that smooth muscle cell-specific CD47 deletion suppresses the disease. Age-related impairments in efferocytosis and autophagy further hinder plaque regression, and recent preclinical work suggests CD47 blockade can reprogram the monocyte-macrophage axis to promote inflammation resolution in atherosclerotic vessels.

Researchers are now engineering delivery systems to exploit this biology with precision. Biomimetic nanoparticles that boost efferocytosis through dual-pathway regulation are being developed for atherosclerosis therapy and imaging, while ROS-responsive liposomes combine CD47 blockade with lipid metabolism regulation to target inflamed plaques. Similar nanotechnology strategies are being applied to the heart: after myocardial infarction, enhanced efferocytosis of dying cardiomyocytes is linked to tissue repair, and acute CD47 blockade during ischemic reperfusion has been shown to enhance phagocytosis-associated cardiac repair in experimental models. Biomimetic nano-degraders targeting the CD47-SIRPα checkpoint and cardiac-homing nanoparticles that suppress SHP-1 are being tested as ways to promote efferocytosis and dampen the inflammation that otherwise remodels and weakens the infarcted heart.

In the nervous system, the story becomes more complicated, because CD47 plays opposing roles depending on context. Microglia, the brain’s phagocytes, must clear myelin debris, dead neurons and protein aggregates, and CD47 on myelin interacts with SIRPα to downregulate this phagocytosis, potentially impeding repair in multiple sclerosis. In experimental autoimmune encephalomyelitis, a model of multiple sclerosis, CD47 antibody blockade suppressed microglia-dependent phagocytosis and impaired recovery, illustrating the pathway’s Janus-like character in autoimmune brain inflammation. In intracerebral hemorrhage, however, CD47-blocking antibodies accelerated hematoma clearance and alleviated brain injury, including in aged animals with intraventricular hemorrhage. Emerging studies also link CD47 to microglial phagocytosis defects in autism models and to synaptic pruning in Alzheimer’s disease, where microglial clearance of amyloid deposits is a central therapeutic goal, and compounds such as luteolin have been reported to promote phagocytosis by inhibiting CD47 pyroglutamation.

The review by Wang and colleagues makes clear that CD47-mediated efferocytosis is not a simple on-off switch but a finely balanced checkpoint whose manipulation must be tailored to each disease. Blocking CD47 unleashes macrophages against tumors and atherosclerotic debris, yet the same intervention can complicate recovery in some autoimmune neuroinflammatory settings, and anemia caused by CD47’s role on red blood cells remains a safety consideration in clinical trials. The next generation of approaches, including engineered antibodies, nanoparticle delivery, combination regimens with chemotherapy, radiotherapy and other immunotherapies, and drugs that modulate CD47 expression epigenetically, aims to sharpen this therapeutic window. As the molecular circuitry of the don’t eat me signal continues to be mapped, the prospect of deliberately tuning cell clearance to resolve inflammation, dissolve plaques and expose tumors to immune destruction is moving steadily from the laboratory toward the clinic.

Subject of Research: CD47-mediated regulation of efferocytosis and its role in cancer, atherosclerosis and neurological disease

Article Title: CD47-mediated efferocytosis in diseases: A comprehensive review

Article References: Wang, C., Yu, S., Kang, J., Yang, S., Pan, Z., Zhao, Y., Li, C., & Zhu, W. (2026). CD47-mediated efferocytosis in diseases: A comprehensive review. Molecular Biology Reports, 53(1), Article 1656. https://doi.org/10.1007/s11033-026-12854-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12854-z

Keywords: CD47, efferocytosis, SIRPα, macrophages, cancer immunotherapy, atherosclerosis, phagocytosis, immune checkpoint, neurodegeneration, glioblastoma, myocardial infarction, inflammation resolution

The significance of the finding lies in how it connects two previously separate threads of biology. CD47 has long been studied in oncology and immunology because it broadcasts a so-called “don’t eat me” signal. When CD47 on a cell’s surface engages its receptor, signal regulatory protein alpha (SIRPα), on macrophages and other myeloid cells, it triggers inhibitory pathways that suppress phagocytosis and efferocytosis, the orderly clearance of dead and dying cells. Cancer cells exploit this signal to evade immune surveillance, which is why anti-CD47 antibodies are being developed as cancer therapeutics. Separately, CD47 also binds thrombospondin-1 and integrins, pathways that regulate nitric oxide signaling, vascular tone, oxidative stress, and cell survival. Prior work has linked CD47 upregulation to cardiac hypertrophy, fibrosis, ischemia-reperfusion injury, and atherosclerosis, while CD47 inhibition has been shown to protect cardiac function in several models.

What remained unknown was whether CD47 participates in cardiac aging itself, particularly the accelerated aging induced by chemotherapy. Clues had been accumulating. In skeletal muscle stem cells, CD47 levels rise with age, and as senescence markers such as beta-galactosidase activity increase, the density of CD47 on the cell surface climbs in parallel, forming what researchers have described as a molecular signature of aging. Aberrant CD47 expression has also been documented in aged fibroblasts, epithelial cells, and red blood cells. Because doxorubicin inflicts a characteristic cascade of injuries on the myocardium, including DNA intercalation, interference with topoisomerase-II-dependent DNA repair, chromatin disruption through nucleosome destabilization and histone eviction, mitochondrial dysfunction, oxidative stress, impaired autophagy, and inflammatory activation, the Chinese team hypothesized that CD47 might serve as the underexplored link between these upstream insults and persistent, age-like cardiac remodeling.

To test this, the researchers first turned to public transcriptomic databases. They analyzed two independent cardiac aging datasets from the Gene Expression Omnibus: a rat dataset (GSE173360) comparing six-month-old adult males with 24-month-old aged animals, and a mouse dataset (GSE225576) comparing young and aged hearts. In both species, CD47 expression was significantly elevated in aged heart tissue, and functional enrichment analysis of the differentially expressed genes revealed alterations in metabolic and myocardial contraction-related pathways. The consistency across two mammalian species suggested that CD47 upregulation is a conserved feature of cardiac aging rather than a quirk of one model system.

The team then built a doxorubicin-induced cardiac aging model in six-month-old male C57BL/6J mice. Animals received weekly intraperitoneal injections of doxorubicin at 2.5 milligrams per kilogram for six consecutive weeks, a regimen designed to mimic the cumulative cardiac stress seen in chemotherapy patients. Molecular analysis confirmed that the model worked: mRNA levels of canonical aging markers, including p53, p16, p21, and the proliferation marker KI67, were markedly elevated in the hearts of doxorubicin-treated mice. Crucially, both the mRNA and protein levels of CD47 were significantly increased in these aged hearts, as demonstrated by quantitative PCR, western blotting, and immunofluorescent staining of cardiac tissue sections.

With the model established, the researchers introduced their therapeutic intervention: ligufalimab, also known as AK117, a humanized IgG4 monoclonal antibody that targets CD47 and blocks its interaction with SIRPα without altering CD47 expression itself. Mice receiving doxorubicin plus weekly ligufalimab at 1 milligram per kilogram showed a striking molecular shift. Expression of the senescence effectors p21 and p16 declined significantly in the heart, indicating that CD47 blockade was not merely improving hemodynamics but was actually dampening the senescence-associated signaling that underlies age-like cardiac remodeling. Echocardiographic assessment, performed after the final dose under pentobarbital anesthesia, told a parallel story. Left ventricular fractional shortening and ejection fraction, the standard functional measures of cardiac pumping performance, dropped sharply in doxorubicin-treated mice compared with saline controls, but ligufalimab co-treatment significantly improved both parameters.

To probe whether the effect was conserved in human cells, the team turned to AC16 cardiomyocytes, a human cardiac cell line derived from a male donor. Cells treated with 0.1 micromolar doxorubicin for 48 hours developed a clear senescence-like phenotype, with p16 and p21 mRNA rising steeply and CD47 mRNA and protein increasing in parallel. When ligufalimab at 0.1 micrograms per milliliter was added alongside the chemotherapy, p21 fell at both the mRNA and protein levels, p16 declined at the mRNA level, and senescence-associated beta-galactosidase staining revealed a notable reduction in cellular aging. The convergence of results from living mouse hearts and cultured human cardiomyocytes strengthens the argument that the protective effect is not species-specific or model-dependent, and it points toward genuine translational relevance.

Mechanistically, the authors propose a compelling explanation centered on the CD47-SIRPα axis. During doxorubicin-induced cardiac injury, upregulated CD47 on stressed or senescent cardiomyocytes may shield those cells from macrophage-mediated clearance, allowing damaged cells to linger and continue broadcasting inflammatory and profibrotic signals throughout the myocardium. By blocking CD47, ligufalimab may restore the removal of injured and senescent cells, limit chronic inflammatory amplification, and thereby interrupt the self-reinforcing loop that converts acute chemotherapy injury into persistent age-like remodeling. The observed reduction in p53, p16, and p21 after CD47 blockade is consistent with this interpretation, suggesting that the antibody attenuates senescence-associated signaling itself rather than simply propping up contractile performance. The finding also reframes CD47 as more than an immune checkpoint molecule: it appears to function as a stress-responsive regulator that integrates cellular damage, immune clearance, and cardiovascular remodeling.

The authors are careful to note that important questions remain before this science can reach the clinic. The downstream mechanisms are not yet fully defined; future work should directly assess SIRPα-dependent efferocytosis, thrombospondin-1/CD47 signaling, mitochondrial function, reactive oxygen species production, inflammatory cytokines, and senescence-associated secretory factors. It is also unclear whether the benefits of anti-CD47 therapy are immune-mediated, intrinsic to cardiac cells, or both, and cell-specific genetic models, macrophage-depletion experiments, and efferocytosis assays will be needed to disentangle these contributions. Because CD47 is broadly expressed and plays essential roles in immune surveillance and red blood cell clearance, clinical translation will demand careful optimization of treatment timing, dose, tissue specificity, and safety. The researchers suggest that transient or cardiac-targeted CD47 inhibition might retain cardioprotective effects while minimizing systemic adverse effects. They also acknowledge that the study focused on male mice and on the heart alone, leaving open whether CD47 regulates aging in other organs and in female animals. Even so, the study marks a notable step: it identifies CD47 as both a potential biomarker of cardiac aging and a druggable contributor to chemotherapy-induced cardiac decline, raising the prospect that oncologists might one day protect the aging heart while still unleashing doxorubicin’s full anticancer power.

Subject of Research: The role of CD47 in doxorubicin-induced cardiac aging and its blockade as a cardioprotective strategy in male mice

Article Title: CD47 is a regulator in doxorubicin‐induced cardiac aging in male mice

Article References: Yan, A., Mai, R., Cao, T., Duan, C., Liu, S., & Wang, X. (2026). CD47 is a regulator in doxorubicin‐induced cardiac aging in male mice. Physiological Reports, 14(18), Article e71111. https://doi.org/10.14814/phy2.71111

Image Credits: AI Generated

DOI: 10.14814/phy2.71111

Keywords: CD47, doxorubicin, cardiac aging, cardiotoxicity, senescence, ligufalimab, SIRPα, efferocytosis, cardiomyocytes, echocardiography, chemotherapy, heart failure

Super-enhancers are unusually large clusters of regulatory DNA sequences bound by high concentrations of transcription factors and co-activators. Unlike ordinary enhancers, which may boost the expression of a single nearby gene, super-enhancers often orchestrate entire cellular identity programs, and in cancer they are frequently hijacked to drive tumor-promoting gene networks. Because these regions are highly accessible, meaning the chromatin there is open and biochemically active, they are prime candidates for studying how genetic variation influences cancer risk and progression. Yet, as the authors of the new study note, the consequences of genomic variants within super-enhancers have remained poorly understood.

The team focused on a regulatory element they describe as bifunctional: a single super-enhancer that simultaneously controls the expression of two genes with very different biochemical outputs. One is LINC00636, a long non-coding RNA, a transcript that is copied from the genome but is not translated into a protein. The other is CD47, a well-known cell-surface protein often called a do-not-eat-me signal because it protects cells from being engulfed by immune cells called macrophages. CD47 is overexpressed in many cancers and has been a major target of experimental immunotherapies. The finding that one super-enhancer governs both a long non-coding RNA and a key immune-evasion molecule immediately suggested a mechanism by which a single DNA change could have layered effects on tumor biology.

Within this super-enhancer, the researchers identified a common germline insertion-deletion variant, or InDel, meaning that some people carry an extra segment of DNA inserted at this position while others do not. Germline variants are inherited and present in every cell of the body, in contrast to the somatic mutations that accumulate during tumor development. The team found that the insertion allele was associated with reduced chromatin accessibility at the super-enhancer locus. In practical terms, when the extra DNA segment is present, the regulatory region appears to be less open, and its activity is dialed down. Chromatin accessibility is a critical variable in gene regulation: open chromatin allows transcription factors and co-activators to bind, while closed chromatin locks them out.

To test whether this correlation reflected a causal relationship, the scientists used gene-targeting techniques to delete the insertion from breast cancer cells grown in the laboratory. The results were unambiguous. Removing the insertion increased chromatin accessibility at the super-enhancer, and this was followed by upregulation of both LINC00636 and CD47. In other words, the insertion acts as a kind of molecular brake on the super-enhancer, and removing the brake lets the two cancer-promoting genes run at higher levels. This experimental design, comparing otherwise identical cells that differ only at the InDel, allowed the researchers to isolate the effect of the variant from the thousands of other genetic differences that normally exist between individuals.

The downstream consequences of deleting the insertion revealed two distinct tumor-promoting programs. The first was mediated by CD47. With more CD47 on their surfaces, the engineered breast cancer cells showed enhanced resistance to apoptosis triggered by nutrient deprivation, the programmed self-destruction that cells normally undergo when starved of essential supplies. Tumors frequently face harsh metabolic conditions as they outgrow their blood supply, and the ability to survive nutrient stress is a recognized hallmark of aggressive cancer. The study’s data indicate that a common inherited variant in a super-enhancer can influence this survival trait through its effect on CD47 expression.

The second program was driven by elevated LINC00636. When the long non-coding RNA was increased, the cells showed activation of senescence, a state in which cells stop dividing but remain metabolically active and often secrete inflammatory signals. Senescence has a complicated relationship with cancer: it can suppress tumor growth directly, but senescent cells in the tumor microenvironment can also promote malignancy through the molecules they release. The authors report that this study establishes a previously unrecognized role for LINC00636 in senescence and breast cancer biology, making the long non-coding RNA a newly identified player in the disease rather than a genomic bystander.

The variant also appeared to reshape the immune landscape around tumor cells. Cells lacking the insertion, and therefore expressing higher levels of CD47, showed reduced infiltration by CD80-positive pro-inflammatory macrophages, the immune cells that help mount an attack against tumors. This observation connects the InDel to the tumor microenvironment, the ecosystem of immune and stromal cells that surrounds a cancer. A single inherited DNA change, by modulating a do-not-eat-me signal, may therefore influence not only how tumor cells behave in isolation but also how the immune system perceives and responds to them.

Taken together, the authors conclude that the insertion allele appears to have a protective role, since its presence dampens the activity of a super-enhancer driving cancer-promoting features. The findings carry several broader implications. For one, they demonstrate that common germline variation within super-enhancers can fine-tune regulatory output in ways that matter for cancer biology, extending the search for functional variants well beyond protein-coding regions and even beyond ordinary promoters and enhancers. For another, the bifunctional nature of the super-enhancer means that a single variant simultaneously influences an immune-evasion gene, a stress-resistance pathway, a senescence program, and immune-cell infiltration, illustrating how compact and interconnected the architecture of cancer gene regulation can be.

The study, which was funded in part by the NIH National Cancer Institute, the California Breast Cancer Research Program, and the Breast Cancer Research Foundation-AACR Career Development Awards, was published as an open-access article and is citable under the DOI 10.1007/s00018-026-06456-y. While the work was performed primarily in cell models and will need to be extended to patient cohorts to determine whether the insertion allele correlates with clinical outcomes, it provides a concrete mechanistic framework for a question that has long hovered over cancer genomics: what do the inherited variants in our non-coding DNA actually do? In this case, the answer is that a small insertion in a super-enhancer can quietly set the volume of two cancer genes at once, with consequences that ripple from chromatin structure all the way to the immune cells surrounding a tumor.

Subject of Research: A germline InDel variant within a bifunctional super-enhancer regulating LINC00636 and CD47 expression in breast cancer

Article Title: An InDel genomic variant within a bifunctional super-enhancer for LINC00636 and CD47 regulation in breast cancer

Article References: Di Benedetto, C., Tsark, A., Acenas, D., Thach, A., Singhal, A., Opazo-Mellado, V., Lemus, A. R., Zeini, M. E., Zhang, H., Park, C., Velozo, H. G., Weissmann, I., & Betancur, P. (2026). An InDel genomic variant within a bifunctional super-enhancer for LINC00636 and CD47 regulation in breast cancer. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06456-y

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06456-y

Keywords: super-enhancer, InDel variant, LINC00636, CD47, breast cancer, chromatin accessibility, long non-coding RNA, senescence, macrophages, gene regulation, cancer genomics, tumor microenvironment

The central problem the researchers set out to address is deceptively simple to state but notoriously difficult to study. When nanoparticles enter the bloodstream, the reticuloendothelial system, a network of macrophage-rich organs dominated by the liver and spleen, recognizes them as foreign material and clears them within minutes to hours. A nanoparticle that is removed from circulation before it can reach a tumor delivers little drug to the disease and much to healthy tissue, compounding toxicity while blunting efficacy. Both PEGylation and red blood cell membrane coating are designed to defeat this clearance, but they do so through entirely different chemistry. PEG is a hydrophilic synthetic polymer that forms a hydration shell around particles, sterically blocking the adsorption of opsonins, the blood proteins that flag foreign material for destruction. Red blood cell membranes, by contrast, carry native ‘self’ markers, most famously the CD47 protein, which engages an inhibitory receptor on macrophages and delivers a molecular ‘don’t eat me’ signal. Yet despite the popularity of both approaches, the field has lacked rigorous head-to-head comparisons in which the only variable is the coating itself.

That gap is precisely what the Fujian team, led by Han Lin, Xiaoqin Wang, and corresponding author Qing Hu, set out to close. Their experimental design hinged on a single, identical nanocarrier core: albumin nanoparticles loaded with doxorubicin, a widely used chemotherapy agent. Albumin has become an attractive scaffold for drug delivery because it is biocompatible, biodegradable, and has a natural affinity for tumors, which scavenger albumin as a nutrient source. Building on this shared platform, the researchers constructed three formulations that differed only in their outermost surface. The first was the bare doxorubicin-loaded albumin nanoparticle, designated DOX-BSA, serving as the unmodified control. The second, DOX-BSA@LPs, was cloaked in PEGylated liposomes, representing the synthetic stealth strategy. The third, DOX-BSA@RMs, was camouflaged with red blood cell membranes, representing the biomimetic strategy. Because all three shared the same core, the same drug payload, and the same underlying particle, any differences in biological behavior could be attributed to the coating rather than to confounding variations in size, charge, or drug loading.

The team then subjected all three formulations to a systematic evaluation spanning physicochemical characterization, cellular behavior, tumor accumulation, and therapeutic performance. The physicochemical work confirmed that the coatings had been successfully applied and that the formulations were suitable for comparison, while the biological assays probed the questions that matter most for nanomedicine: how readily tumor cells take the particles up, how deeply the particles penetrate into tumor-like tissue, how much drug actually accumulates in tumors relative to healthy organs, and ultimately how well the treatments shrink tumors in living animals.

The first headline result was that both stealth strategies clearly worked. Compared with the unmodified DOX-BSA nanoparticles, both the PEGylated liposome-coated and the red blood cell membrane-coated versions showed significantly enhanced tumor accumulation and significantly improved anti-tumor efficacy, with the differences reaching statistical significance at the P < 0.05 threshold. This confirms, on a controlled albumin platform, the core premise of stealth nanotechnology: disguising the surface of a nanocarrier allows it to evade immune clearance long enough to reach its target. For a field in which many comparisons are confounded by differences in particle design, this clean demonstration of the stealth effect itself is a valuable benchmark.

But the more provocative finding lay in the comparison between the two coatings. Across multiple endpoints, the red blood cell membrane formulation, DOX-BSA@RMs, showed marginal yet statistically significant advantages over its PEGylated counterpart, DOX-BSA@LPs. In three-dimensional tumor spheroids, laboratory models that mimic the dense, poorly vascularized architecture of real tumors, the membrane-camouflaged particles penetrated deeper than the PEGylated ones. Penetration depth is a critical variable in solid tumor therapy because chemotherapeutics must reach not just the cells at the tumor periphery but the inner mass, where hypoxic and quiescent cells often survive treatment and seed relapse. A coating that improves access to the tumor interior could therefore translate into more complete tumor kill.

Histological examination of treated tumors reinforced the pattern. Tumors from animals treated with the red blood cell membrane formulation displayed more extensive necrosis and apoptosis, the two hallmarks of effective chemotherapy response, than tumors treated with the PEGylated formulation. Consistent with this, the membrane-coated particles achieved a higher tumor inhibition rate overall, meaning they shrank tumors more effectively in vivo. The researchers also measured tumor-to-normal-tissue ratios, a pharmacokinetic metric that captures how selectively a formulation homes in on tumors versus healthy organs, and found the ratios were superior for the membrane-camouflaged particles, indicating higher tumor accumulation relative to off-target deposition. Higher selectivity is the holy grail of chemotherapy, since it promises greater efficacy with fewer of the dose-limiting side effects, such as cardiotoxicity, that plague conventional doxorubicin.

Why might a biological membrane outperform a synthetic polymer, even if only by a modest margin? The authors’ findings are consistent with mechanistic ideas that have been accumulating in the literature. PEG, despite its success in products such as the liposomal doxorubicin formulation Doxil, the first FDA-approved nano-drug, is not without liabilities. Anti-PEG antibodies exist in a substantial fraction of the population, likely owing to widespread exposure to PEG-containing products, and recent work has shown that such antibodies can become enriched in the protein corona that forms around PEGylated nanocarriers, potentially accelerating clearance and altering cellular uptake on repeated dosing. Red blood cell membranes, by contrast, present a native repertoire of self-markers, including CD47, whose role as a ‘marker of self’ on erythrocytes was established in landmark work published in Science in 2000. In addition, membrane coatings preserve the mechanical deformability that allows red blood cells to squeeze through narrow capillaries, a property that some studies suggest may aid circulation and tissue penetration in ways that rigid synthetic coatings cannot replicate.

The significance of the study lies as much in its methodology as in its results. By fixing the core and varying only the coating, the researchers established what they describe as a comparative paradigm for evaluating nano-coatings, one that removes the confounders that have made it difficult to judge competing stealth strategies on their merits. Previous reviews of the field, including a 2024 analysis of stealth coatings in cancer models published in ACS Applied Materials and Interfaces, have noted that direct comparisons under uniform conditions are rare, leaving formulators to choose between PEGylation and membrane coating largely on the basis of precedent rather than evidence. The Fujian study provides that evidence for the albumin-doxorubicin system, and its framework can be readily applied to other payloads and other coating chemistries, from macrophage membranes to platelet membranes to hybrid coatings that combine features of several cell types.

Caveats remain, as they always do in preclinical nanomedicine. The advantages of the red blood cell membrane coating, while statistically significant, were described by the authors as marginal in magnitude, and the study evaluated a single drug, a single core material, and a single tumor model. Red blood cell membrane coatings also raise practical questions about sourcing, standardization, and scale-up that synthetic polymers do not, and the long-term immunological behavior of membrane-cloaked particles in repeat-dose regimens will require further study. Nevertheless, the work marks an important step toward rational, evidence-based design of nanocarrier surfaces. As cancer nanomedicine matures from proof-of-concept demonstrations toward optimized clinical formulations, studies that isolate the contribution of each design choice, rather than changing everything at once, are exactly what the field needs. On the evidence assembled by the Fujian Medical University team, when it comes to hiding a nanoparticle from the immune system long enough to deliver a lethal payload to a tumor, nature’s own disguise appears to hold a slight but real edge over the best synthetic imitation.

Subject of Research: Comparison of PEGylation and red blood cell membrane stealth coatings on doxorubicin-loaded albumin nanoparticles for antitumor drug delivery

Article Title: Comparison of PEGylation versus red blood cell membrane camouflage strategies: in vivo and in vitro antitumor efficacy of doxorubicin-loaded albumin nanoparticles

Article References: Lin, H., Wang, X., Lin, Z., Dai, T., Qiu, X., Yu, X., Yu, Y., & Hu, Q. (2026). Comparison of PEGylation versus red blood cell membrane camouflage strategies: in vivo and in vitro antitumor efficacy of doxorubicin-loaded albumin nanoparticles. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00831-4

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00831-4

Keywords: nanoparticles, drug delivery, PEGylation, red blood cell membrane, doxorubicin, albumin nanoparticles, stealth coating, tumor accumulation, cancer therapy, nanomedicine, biomimetic coating, CD47